TD-1211 demonstrates a durable increase in bowel movement frequency and return toward normal bowel function in a 5-week Ph2b Opioid-Induced Constipation (OIC) study
R. Vickery(Theravance Biopharma (United States)), D. M. Canafax(Theravance Biopharma (United States)), Lynn R. Webster(Adherent Technologies (United States)), Neeraj Singla(Theravance Biopharma (United States)), Yuhong Li(Theravance Biopharma (United States)), Ullrich Schwertschlag
Cited by 8
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304